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Background
Biologic therapy has been used for over 10 years and is
increasingly used in the treatment of many chronic inflam-
matory diseases. At the present time it has a very broad
range of applications: rheumatic, dermatologic, gastro-
intestinal, neurologic and neoplastic diseases. Biologic
therapy is represented by immunomodulator agents (anti-
bodies or other peptides) that interfere with the regular
humoral immune response. Thus, in addition to the bene-
ficial effects in relation with the underlying disease it may
lead to opportunistic infections: bacterial, viral, fungal, or
parasitic.
Study hypothesis
Opportunistic infections in patients on biological therapy
may represent cause for concern, given the increased risks
of infection in this category of patients. Our objective is to
conduct a study on two research directions:
1) A prospective, observational study which will consist
of a group of patients undergoing treatment with biologic
agents and a control group. Study visits will occur at the
baseline, and then every 24 weeks plus unscheduled visits
when required in case of infections. We will evaluate the
following parameters: blood tests (CBC, biological inflam-
matory syndrome, coagulation, biochemistry), cytokines
values, QuantiFERON TB Gold, urine analysis, blood cul-
tures and nasal, pharyngeal and axillary carriage.
2) A retrospective study (statistical analysis) of the
already existing data collected in Romanian Registry of
Rheumatic Diseases which contains an up to date list of all
the patients with RA (within the country) currently under-
going biological therapy.
Expected Results
The objectives of the study are: to determine the rate of
occurrence of intercurrent and opportunistic infections in
patients undergoing biological therapy within the country
(data which is not available at the moment), to compare
this information with the available external data and to
define a particular profile for patients susceptible to sec-
ondary infections due to biological therapy.
Acknowledgement
This paper is partially supported by the SOP HRD, financed from the
European Social Fund and by the Romanian Government under the contract
numbers POSDRU/159/1.5/S/137390.
Authors’ details
1Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.
2National Institute for Infectious Diseases “Prof. Dr. Matei Balş”, Bucharest,
Romania. 3“Sf. Maria” Clinical Hospital, Bucharest, Romania.
Published: 15 October 2014
doi:10.1186/1471-2334-14-S7-P40
Cite this article as: Popescu et al.: Intercurrent and opportunistic
infections in patients treated with biological agents: study hypothesis.
BMC Infectious Diseases 2014 14(Suppl 7):P40.
* Correspondence: ramona_fany@yahoo.com
1Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
Full list of author information is available at the end of the article
Popescu et al. BMC Infectious Diseases 2014, 14(Suppl 7):P40
http://www.biomedcentral.com/1471-2334/14/S7/P40
© 2014 Popescu et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
